Compare Incyte Corporation (INCY) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Suncor Energy Inc. — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Suncor Energy Inc. trades at $61.95 (market cap $72.86B). The key difference: Suncor Energy Inc. is far larger — about 3.2× Incyte Corporation's market cap, and Suncor Energy Inc. pays a 2.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SU | |
|---|---|---|
Market Cap | $23.11B | $72.86B |
Sector | Health | Energy |
52-Week High | $118.52 | $69.73 |
52-Week Low | $67.38 | $38.17 |
Enterprise Value | $19.13B | $80.99B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Suncor Energy (SU) trades at $62.62, up 0.3% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with a P/E of 16.85, net income margin of 11.62%, and consistent earnings beats in recent quarters. Recent news highlights operational improvements and record production driving the stock's 49% annual gain. Cash flow remains positive with $166M net cash flow in 2025, supported by disciplined capital allocation.
SU presents a compelling investment case with attractive valuation metrics and strong institutional support, though exposure to oil price volatility and recent RSI overbought signals warrant caution. The company's integrated operations and shareholder returns provide stability, but investors should monitor commodity price trends and Q2 earnings results against the $2.14 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
